Affective Touch, Hedonia and Suicidal Behavior (TOUCH-S)

January 8, 2025 updated by: University Hospital, Montpellier

Several elements suggest that suicidal vulnerability may be associated with an alteration in the perception of affective touch. On the one hand, anhedonia, characterized by a decrease in the pleasure felt, is strongly associated with suicidal ideation, independently of depression. However, the ability to feel pleasure is essential in the perception of affective touch. On the other hand, suicidal behaviors are associated with interpersonal difficulties, of which communication is an integral part, and communication is partly through touch.

The investigators therefore wish to explore the perception of affective touch in suicidal behavior by using an affective tactile stimulation in 72 subjects with and without a history of suicide attempts (SA).

Study Overview

Detailed Description

This study aims to compare the perceived hedonic nature of affective touch in euthymic subjects with a history of SA and euthymic subjects without a history of SA.

The investigators also aim to :

  • compare the perceived hedonic nature of non-affective touch in this population;
  • compare the perceived intensity of affective touch;
  • compare the perceived intensity of non-affective touch;
  • study the association between decision making performance and perceived pleasantness of affective vs. non-affective touch;
  • study the association between plasma beta-endorphin levels and the perceived pleasantness of affective vs. non-affective touch;
  • study the effect of the tactile stimulation on the expression of opioidergic genes, by comparing the mRNA levels of 6 genes coding for opioidergic receptors and peptides before and after tactile stimulation;
  • investigate the association between tactile stimulation-related opioidergic gene expression variation and the perception of the pleasantness of affective versus non-affective touch.

To do so, 72 euthymic women will be included and divided in two groups: 1) Euthymic patients with a lifetime history of major depressive episode and a history of suicidal behavior; 2) Euthymic patients with a lifetime history of a major depressive episode and no history of suicidal behavior.

Participants will be subjected to tactile stimulation (affective and non-affective), following a clinical and neurospychological assessment. During the experimental touch, participants will be asked to evaluate the pleasantness of the touch and its intensity. In addition, blood samples will be taken before and after the stimulation.

Participation will be done in one day or in two visits, up to 72 hours apart.

The investigators expect: 1) subjects with a history of TS to have a decreased perceived pleasantness of affective touch compared to subjects without a history of TS; 2) the difference between the perceived pleasantness of affective versus non-affective touch to be smaller in patients with a history of TS; 3) decision making to be related to the hedonic nature of affective touch; 4) a change in the expression of opioidergic genes.

This study will contribute to a better knowledge of the vulnerability to suicidal behaviors and to a better understanding of psychopathology in order to offer specific and more adapted prevention and management strategies.

Study Type

Interventional

Enrollment (Actual)

72

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Montpellier, France, 34295
        • Montpellier University Hospital, France (CHU)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Being a woman
  • Aged between 18 and 65
  • Past major depressive episode according to the DSM-5 criteria
  • Currently euthymic (Montgomery-Asberg Depression rating Scale (MADRS) < 12 and Young Mania Rating Scale (YMRS) < 6)
  • Minimal psychotropic medication (as determined by the clinician)
  • Able to understand experimental procedures
  • Able to speak, read and understand French
  • Having given written informed consent
  • For suicide attempters only: Lifetime history of suicide attempt
  • For affective controls only: No lifetime history of suicide attempt

Exclusion Criteria:

  • Lifetime diagnosis of schizoaffective disorder, schizophrenia or autism spectrum disorder
  • Severe alcohol or substance use disorder in the past 6 months
  • Current anorexia nervosa
  • Diagnosis of mental retardation or severe medical comorbidity that is unstable or could interfere with measures (HIV, diabetes, cancer, chronic inflammatory disease, neurological disorder, sensory or cognitive disability)
  • Injury, scar, irritation/dermatological lesion or tattoo on the left forearm
  • Pregnancy or breastfeeding
  • Being in exclusion period for another study
  • Not being affiliated to the French National Social Security System
  • Being deprived of freedom (by judicial or administrative decision)
  • Being protected by law (guardianship or curatorship)
  • Having reached 4500€ annual compensation for participating to clinical trials

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Euthymic patients with history of suicide attempt (suicide attempters)
Currently euthymic patients with at least one lifetime major depressive episode and a history of suicide attempts

The experimental task aims to evaluate the hedonic nature of an affective touch by tactile stimulation.

It consists in stimulating two adjacent regions of the left forearm, delimited and marked, of 9 cm x 4 cm each. In order to limit habituation, the stimulation areas will be alternated.

To stimulate these areas, the investigator (previously trained) strokes the participant with a brush at an optimal speed to stimulate the C-fibers (3 cm/s; slow speed) or not (18 cm/s; fast speed).

Touch will consist of 30 seconds blocks of stimulation, performed on one of the two identified areas, from the elbow to the wrist. In total, 6 stimulation blocks will be done (3 slow and 3 fast), the order and location of which will be random in order to limit habituation.

This stimulation is completely painless. After each block, the participant will evaluate the intensity of the stimulation and its pleasantness.

Experimental: Euthymic patients without any history of suicide attempt (affective controls)
Currently euthymic patients with at least one lifetime major depressive episode and with no history of suicide attempts

The experimental task aims to evaluate the hedonic nature of an affective touch by tactile stimulation.

It consists in stimulating two adjacent regions of the left forearm, delimited and marked, of 9 cm x 4 cm each. In order to limit habituation, the stimulation areas will be alternated.

To stimulate these areas, the investigator (previously trained) strokes the participant with a brush at an optimal speed to stimulate the C-fibers (3 cm/s; slow speed) or not (18 cm/s; fast speed).

Touch will consist of 30 seconds blocks of stimulation, performed on one of the two identified areas, from the elbow to the wrist. In total, 6 stimulation blocks will be done (3 slow and 3 fast), the order and location of which will be random in order to limit habituation.

This stimulation is completely painless. After each block, the participant will evaluate the intensity of the stimulation and its pleasantness.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pleasantness of the touch
Time Frame: at inclusion
Perceived pleasantness of the tactile stimulation, assessed with a numeric scale ranging from -5 (very unpleasant) to +5 (very pleasant)
at inclusion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intensity of the touch
Time Frame: at inclusion
Perceived intensity of the tactile stimulation, assessed with a 10 points Likert scale (low intensity to high intensity).
at inclusion
Decision-making performance (Iowa Gambling Test)
Time Frame: at inclusion
Decision-making performance using the IG index from the Iowa Gambling Test (difference between the number of safe and risky choices)
at inclusion
Decision-making performance (Ultimatum Game)
Time Frame: at inclusion
Decision-making performance using the UG index from the Ultimatum Game (difference between the number of rejections of unfair and fair offers)
at inclusion
β-endorphin levels
Time Frame: at inclusion
Plasmatic levels of β-endorphin
at inclusion
Variation in the expression of opioidergic genes
Time Frame: at inclusion
Variation in mRNA levels of 6 genes coding for opioidergic receptors and peptides (OPRM1 (µ), OPRK1 (κ), OPRD1 (δ) and pro-opio-melanocortin, pro-enkephalin, pro-dynomorphin), before and after tactile stimulation
at inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 11, 2022

Primary Completion (Actual)

September 9, 2024

Study Completion (Actual)

September 9, 2024

Study Registration Dates

First Submitted

December 22, 2021

First Submitted That Met QC Criteria

December 22, 2021

First Posted (Actual)

January 10, 2022

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 8, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RECHMPL21_0502

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Major Depressive Episode

Clinical Trials on Tactile stimulation

Subscribe